Rigetti Computing secures a significant order to deliver a 108-qubit quantum system to India's Centre for Development of Advanced Computing, marking a key commercial milestone and international expansion for the company amidst volatile stock performance.
Barclays PLC announces a series of senior leadership appointments across its securitized products, payments, and European operations, signaling strategic focus areas as it prepares to relocate its EU hub to Paris.
The Texas-born travel center giant Buc-ee's is renowned for massive stores and spotless restrooms. But its most disruptive industry practice might be its pay scale, which far exceeds typical convenience store wages and fuels intense competition for jobs.
Amazon has filed a WARN notice indicating it will permanently eliminate 2,198 positions across multiple locations in Washington state by late April 2026, adding to a wave of corporate restructuring that has already seen thousands of layoffs in the region.
Nearly half of U.S. employers are shifting from merit-based raises to flat, across-the-board pay increases—a move that could provide crucial relief for lower-wage workers amid economic uncertainty.
Canopy Growth's shares have plummeted over 99% in five years, yet analysts warn its challenges run deeper than its stock price suggests. Despite recent U.S. regulatory changes, structural industry headwinds and the company's own track record make it a speculative play at best.
As the energy sector leads the market in early 2026, ConocoPhillips and Kinder Morgan emerge as compelling picks for investors seeking reliable, growing dividends backed by strong fundamentals and strategic positioning.
As economic anxieties mount, strategic diversification remains paramount. We examine two Vanguard ETFs that could offer stability and long-term growth opportunities should market conditions deteriorate.
The severe winter storm Fern, leaving nearly a million customers without power, has starkly highlighted the U.S. electrical grid's persistent vulnerabilities. This comes despite repeated warnings from reliability monitors about the system's growing strain.
As Microsoft shares trade nearly 12% below recent highs, some analysts see a buying opportunity. We explore how selling put options could offer investors a strategic entry point while generating income.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
In an unusual acquisition within the ETF space, the investment arm behind former President Donald Trump's social media platform is set to purchase the conservative-themed 'God Bless America' ETF, significantly expanding its asset base and adding active management to its lineup.
PLS Group (ASX:PLS) receives significant forecast upgrades from analysts, with revenue projections for 2026 raised to AU$1.6b and the company expected to return to profitability this year.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
CNBC's Jim Cramer offered a measured take on data security firm Rubrik (NYSE:RBRK), suggesting investors wait for market volatility to settle before considering a position, while highlighting the crowded nature of the sector.
CNBC's Jim Cramer positions Alphabet as the potential 'only winner in AI,' suggesting its upcoming earnings may show it generating more revenue from AI than rival Meta Platforms.
CNBC's Jim Cramer suggests investors watch for a pullback in Microsoft shares, praising its leadership but expressing concern that the tech giant's AI investments may not be optimally targeted to meet soaring demand.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
Goldman Sachs' investment arm leads a major funding round in Fieldguide, an AI platform for auditors and accountants, signaling a strategic push into the automation of professional services and a potential new growth vector for the Wall Street giant.
As the ASX braces for a turbulent February amid rate hike fears, a closer look reveals resilient micro-caps with unique value propositions. We analyze three sub-$150M companies—from healthcare tech to critical minerals—that are navigating the volatility with strong balance sheets and niche market positions.
